Prevention Of Pertussis From Birth Through Maternal Immunisation
Funder
National Health and Medical Research Council
Funding Amount
$197,657.00
Summary
Whooping cough or pertussis is a significant cause of death in infants worldwide. Newborns remain at risk until they have received 1 to 2 doses of pertussis vaccine (around 4 months of age). My project involves investigating whether giving pertussis vaccine in the third trimester of pregnancy provides passive protection (via transplacental transfer of antibody) to the infant in sufficient levels for protection against whooping cough in early infancy.
Assessing Vaccine Effectiveness Of Publicly Funded Vaccination Programs In Queensland
Funder
National Health and Medical Research Council
Funding Amount
$99,883.00
Summary
I will measure how well three vaccines on the national immunisation schedule prevent disease in Queensland. Pertussis (whooping cough), rotavirus, and varicella (chicken-pox) vaccines will be assessed using routinely collected health data, such as disease notifications and hospitalisations, and vaccination data. The findings of this research will contribute to evaluating the effectiveness of these publicly funded vaccination programs and will provide an evidence base for future decision-making.
The Immunogenicity Of 7-valent Pneumococcal Conjugate Vaccine In Sick Elderly People For Whom Vaccine Is Not Registered
Funder
National Health and Medical Research Council
Funding Amount
$443,800.00
Summary
The bacteria pneumococcus (also known as streptococcus pneumoniae) is the most common cause of pneumonia in the community, and a major cause of illness and death in the elderly. Rates of antibiotic resistance are also increasing. The pneumococcus is a complex bacteria, with over 80 known serotypes. Most human disease in Australia is caused by 23 of these serotypes. Australia has an ageing population. The health and wellbeing of the elderly has been identified as a national priority. Vaccination ....The bacteria pneumococcus (also known as streptococcus pneumoniae) is the most common cause of pneumonia in the community, and a major cause of illness and death in the elderly. Rates of antibiotic resistance are also increasing. The pneumococcus is a complex bacteria, with over 80 known serotypes. Most human disease in Australia is caused by 23 of these serotypes. Australia has an ageing population. The health and wellbeing of the elderly has been identified as a national priority. Vaccination and prevention of serious infections, a common cause of illness in the elderly, is an achievable public health goal. The National Health and Medical Research Council (NHMRC) of Australia recommends that adults aged 65 years and over should be immunised with 23-valent polysaccharide pneumococcal vaccine (PPV). PPV has been available long term in Australia, but the dilemma associated with its use is that it is least effective in those at greatest risk of pneumococcal disease and its complications, the sick elderly population. A new 7-valent pneumococcal conjugate vaccine (PCV-7) has been available since the end of 2000, but is currently indicated only for children, because it has never been tested in adults. This vaccine uses different technology, and is conjugated to a protein to make it more effective. Clinicals trials of PCV7 have largely been limited to children aged 0-4 years, and have shown it protects 93.9% of children under 2 years of age against invasive pneumococcal disease (IPD). Our study aims to look at the efficacy of this new vaccine, currently only registered for children, in the sub-group of the population who are at highest risk for pneumococcal disease - hospitalised elderly. We will vaccinate hospitalised elderly people with PCV or PPV and compare their immune response to the two different vaccines. If PCV is more effective than PPV, this has implications for the development and use of conjuagated pneumococcal vaccines for adults.Read moreRead less
Q Fever: How Common Is It And How Can We Best Prevent It? Research To Inform Q Fever Vaccine Policy In Australia And Internationally
Funder
National Health and Medical Research Council
Funding Amount
$743,376.00
Summary
Q fever is a disease of worldwide importance which has special significance for Australia where outbreaks continue to occur. We will measure the burden of Q fever in the Australian population for the first time, measure how long immunity lasts following vaccination, collect extra information on adverse events in young adults and survey knowledge and attitudes of Q fever disease and vaccine. The results will inform policies for the control of Q fever in Australia and internationally.
Immunisation In Under Studied And Special Risk Populations: Closing The Gap In Knowledge Through A Multidisciplinary Approach
Funder
National Health and Medical Research Council
Funding Amount
$2,499,969.00
Summary
Much of the vaccine research which informs national policy is conducted by the pharmaceutical industry or by government. However, there are critical research gaps in special-risk and under-served populations where targeted research is not commercially viable. These include research in the extremes of age, Indigenous Australians, migrants, refugees, immunosuppressed and traveller populations. This CRE will address research gaps in such populations, which have not been addressed elsewhere, using n ....Much of the vaccine research which informs national policy is conducted by the pharmaceutical industry or by government. However, there are critical research gaps in special-risk and under-served populations where targeted research is not commercially viable. These include research in the extremes of age, Indigenous Australians, migrants, refugees, immunosuppressed and traveller populations. This CRE will address research gaps in such populations, which have not been addressed elsewhere, using novel, multidisciplinary methods.Read moreRead less
Links2HealthierBubs: Influenza And Pertussis Vaccine Effectiveness And Safety In Pregnancy
Funder
National Health and Medical Research Council
Funding Amount
$676,333.00
Summary
Vaccination during pregnancy can offer protection against severe respiratory disease for infants in the first six months of life. For this reason, influenza and pertussis vaccines are routinely recommended during each pregnancy. Unfortunately, little is known about the ‘real world’ effect of both vaccines. We plan to conduct the largest and most comprehensive study to date to evaluate all vaccines routinely recommended in pregnancy in Australia.
Case-cohort Study Of The Association Between Pertussis Vaccination In Infancy And The Risk Of IgE-mediated Food Allergy.
Funder
National Health and Medical Research Council
Funding Amount
$144,742.00
Summary
Allergic diseases are one of the most important causes of chronic morbidity among children in Australia. This is a retrospective case-controlled trial, utilising data from the Australian immunisation register and cases of confirmed food allergy, to examine the role of vaccination in protection against food allergy. If a relationship between the type of vaccination and protection against allergy is found, this would have implications for allergy prevention and immunisation policy.
Evaluation And Optimisation Of Paediatric Vaccination Programs In Australia And The Region
Funder
National Health and Medical Research Council
Funding Amount
$293,426.00
Summary
Vaccines are highly effective in preventing infection. Increasing numbers of vaccines are available to children and to national immunisation programs. Research is required to ensure that vaccines included in national programs are effective and safe. We must also understand why some children are not vaccinated and to assess ways to improve uptake. Focusing on two common disease, influenza and pneumococcal disease, this fellowship will address these unanswered questions.
Providing The Evidence To Guide Adult Immunisation Strategies
Funder
National Health and Medical Research Council
Funding Amount
$492,414.00
Summary
Australia's population is ageing and strategies to improve health in older adults are necessary to prevent an increasing burden on our health system. Adult vaccination is a relatively under-researched area with great potential to prevent disease in the population. This project focuses on four common vaccine preventable disease in adults, herpes zoster (shingles), influenza, invasive pneumococcal disease and pertussis. It will identify what their impact is on the health system and what groups of ....Australia's population is ageing and strategies to improve health in older adults are necessary to prevent an increasing burden on our health system. Adult vaccination is a relatively under-researched area with great potential to prevent disease in the population. This project focuses on four common vaccine preventable disease in adults, herpes zoster (shingles), influenza, invasive pneumococcal disease and pertussis. It will identify what their impact is on the health system and what groups of adults would benefit most from vaccination.Read moreRead less